Abstract-Although factors such as age, blood pressure, and its responsiveness to changes in sodium balance and extracellular fluid volume status (salt sensitivity) are associated with an increased risk of end-organ disease and cardiovascular events in hypertensive subjects, no such relationship with mortality has been demonstrated for salt sensitivity in normotensive subjects. We conducted long-term follow-up of 430 normal and 278 hypertensive subjects in whom assessment of salt sensitivity of blood pressure was performed as long as 27 years ago. We ascertained the status of 596 subjects (85% of the total population), 123 (21%) of whom had died. The following initial measurements were significantly (PϽ0.002) associated with subjects who had died compared with subjects known to be alive: age at study, pulse pressure, systolic, diastolic, and mean arterial pressures, hypertension, salt sensitivity, baseline renin levels, and body mass index (but not body weight). A stepwise logistic regression found the following independent predictors of death (odds ratio, 95% CI): age at initial study (1.08, 1.06 to 1.10), baseline blood pressure (1.03, 1.01 to 1.04), sodium sensitivity (1.73, 1.02 to 2.94), and male gender (1.91, 1.15 to 3.17). When survival curves were examined, normotensive salt-sensitive subjects aged Ͼ25 years when initially studied were found to have a cumulative mortality similar to that of hypertensive subjects, whereas salt-resistant normotensive subjects had increased survival (PϽ0.001).
I ndividuals with elevated blood pressure are at increased risk for cardiovascular (CV) events and death. Tedious and massive outcome studies have been mounted to demonstrate the benefit of various interventions in high-risk populations, but these studies have relied largely on surrogate measures to infer preventive or therapeutic benefits. In addition to systolic, diastolic, and mean arterial pressures, such surrogates have included pulse pressure, nocturnal blood pressure patterns, and responses of blood pressure to the manipulation of sodium and extracellular fluid balance by different techniques. These techniques have permitted identification of salt sensitivity and salt resistance or insensitivity among normotensive as well as hypertensive subjects. [1] [2] [3] [4] Despite differences in the techniques and criteria used for the definition of salt sensitivity and resistance by different investigators, congruence and reproducibility of the responses have been demonstrated in the majority of carefully performed studies. 5 A variety of demographic, physiological, and genetic characteristics differentiate these groups. 5 Recent observations suggest that differences also exist in the endorgan effects. 6, 7 For example, salt sensitivity has been linked to an increased risk for the development of left ventricular hypertrophy, proteinuria, and a blunted nocturnal decline in blood pressure ("non-dipping"). 6 -8 In addition, among Japanese hypertensive subjects, CV events were found to be twice as common among salt-sensitive hypertensives compared with their salt-resistant cohort. 6 More than 25 years ago, we conducted studies in 430 normal and 278 hypertensive subjects that enabled us to define salt sensitivity and resistance and to identify the phenomenon for the first time in normotensive subjects. 4 These studies also demonstrated the congruence of blood pressure responses to a rapid sodium and volume manipulation maneuver with dietary sodium alterations. 5 Our present study enabled us to locate or obtain information on the vital status of 85% of the original cohort. We sought to test the hypothesis that salt sensitivity in normotensive as well as in hypertensive subjects is associated with an increased risk of CV events and reduced survival. We now report the factors that we found to be associated with death in 123 subjects.
Methods
The study cohort consisted of 708 subjects aged 18 to 80 (34Ϯ15 [meanϮSD]) years when initially studied; it included 313 women (44.2%), 178 African Americans (25%), 278 hypertensive subjects (39.3%), and 338 subjects who were subsequently deemed to be salt sensitive (50%) (see below). 4 The assessment of the blood pressure response to salt at the initial study required the withdrawal of antihypertensive drug therapy for at least 2 weeks in hypertensive subjects and excluded women receiving oral contraceptives or hormone replacement therapy. On the day after admission to the Clinical Research Center, sodium loading and volume expansion were achieved by the intravenous administration of 2 L normal (0.9%) saline between 8:00 AM and noon. The average of the last 2 of 3 blood pressure measurements made after 2 hours of ambulation before the saline infusion was taken as the baseline "presaline" mean arterial blood pressure (MABP). MABP was derived from the following formula: diastolic pressureϩ1/3 pulse pressure. At the end of the saline infusion, blood pressure was again measured to determine the "postsaline" MABP. On the next day, sodium and volume depletion were accomplished by administration of a 10 mmol sodium diet and three 40-mg doses of furosemide given at 10:00 AM, 2:00 PM, and 6:00 PM. The blood pressure was again measured 3 times after 2 hours of ambulation the following morning at 8:00 AM, and the "postfurosemide" MABP was calculated. Salt sensitivity of blood pressure was defined as a decrease in MABP Ն10 mm Hg, and salt resistance was defined as a decrease Ͻ6 mm Hg and included those subjects demonstrating an increase in blood pressure after sodium and volume depletion. 4 Decreases in MABP between 6 and 9 mm Hg were considered indeterminate with respect to sodium sensitivity. Plasma renin activity was measured from venous blood obtained at each interval of blood pressure measurement during the initial study. 4 The Indiana University Institutional Review Board approved all studies, and informed consent was obtained from all subjects at the time of the initial study. For the follow-up study, information regarding vital status was obtained from the subject, from the next-of-kin, and/or from public death registries (eg, the National Death Index and the Indiana State Board of Health Vital Statistics Bureau). Subjects were located by hospital records, by public directories, and by using the services of a locating firm (Find People Fast). A form letter inviting participation in follow-up studies (including a health questionnaire and a brief outpatient study) was sent to the last current address. This also included an informed consent form for those agreeing to further participation or for the next of kin in the case of deceased subjects. Health information and cause of death were obtained from death certificates and from the next of kin when available. Subjects were classed as alive, dead, or unknown on the basis of the most recent information. CV death was defined as death due to myocardial infarction, ischemic heart disease, rheumatic heart disease, congestive heart failure, cardiogenic shock, cardiac arrhythmia, cardiac arrest, cerebrovascular disease, or stroke.
Subject identification information did not include an entire name. Raw data identifying the subject by name was kept in a locked room with limited access. Statistical analyses were conducted with the use of t tests, the Fisher exact test, forward stepwise logistic regression, and forward stepwise Cox proportional hazards regression. Because the date of death could not be ascertained for all subjects, we performed logistic regression analyses for all decedents and Cox proportional hazards analyses for those for whom the date of death was known. Kaplan-Meier survival curves were constructed and compared with the use of a log rank test. We also examined survival of the population adjusted for age into 3 roughly equal groups (Ͻ25 years, 25 to 45 years, and Ͼ45 years at initial study). In the case of measures that were not normally distributed, such as plasma renin activity, 4 square root transformation was performed to normalize the data for analyses. Data are presented as meanϮSD. A value of PϽ0.05 was considered to be significant. For hazard analyses, we present odds ratios (ORs) and 95% CIs.
Results
Information was obtained for 596 subjects representing 85% of the original cohort, of whom 123 (20.6%) had died. The 112 subjects who could not be located (15% of the population) were significantly younger at the time of the initial study (28.6Ϯ10.1 versus 34.8Ϯ15.0 years, PϽ0.001) and were more likely to be African American (44.6% versus 22.1%, PϽ0.001) than those who were ascertained.
As noted in Table 1 , the subjects who had died were significantly older when they were initially studied (48Ϯ14 versus 31Ϯ13 years, respectively; PϽ0.001), had a shorter follow-up time (15Ϯ6 versus 23Ϯ4 years, respectively; PϽ0.01), and were more likely to be hypertensive at the initial study (63.4% versus 33.8%, respectively; PϽ0.001) and salt sensitive (73.4% versus 44.9%, respectively; PϽ0.001) than were those who survived. There were no significant differences in the race or gender distributions of those who survived compared with those who had died. As shown in Table 2 , the subjects who had died compared with those who survived had a higher body mass index (26.9Ϯ5.2 versus 25.5Ϯ5.6, respectively; Pϭ0.027) but not body weight (75.5Ϯ15.2 versus 73.5Ϯ17.1 kg, respectively; Pϭ0.238) when they were initially studied. Although the data are not presented, the men were significantly (PϽ0.001) taller than the women, but there were no differences in height between deceased and surviving subjects. Initial study blood pressures (Table 3) were significantly higher among those who subsequently died compared with those who survived for baseline (Figure) , was significant. This term was coded as 1 for subjects who were normotensive and sodium resistant and as Ϫ1 for all others. The hazards ratio was 0.56 (CI 0.38 to 0.82, Pϭ0.002), indicating that being normotensive and sodium resistant at the initial study improved survival.
As shown in the Figure, which depicts Kaplan-Meier cumulative survival curves analyzed by log rank test, the survival curves for individuals who were normotensive and salt sensitive at the time of the initial study were not different from those of initially hypertensive subjects. The only group in whom survival was significantly better (PϽ0.001) was normotensive subjects in whom salt resistance of blood pressure was initially observed. When the age-stratified Kaplan-Meier survival analyses were performed in the 3 age groups and pooled, the log rank test was significant (PϽ0.006). Within age groups, the effect of salt sensitivity on survival was borderline for the 2 older groups (Pϭ0.065 and Pϭ0.075) and not significant in those aged Ͻ25 years at the time of the initial study.
CV causes of death were identified for 60 of the decedents. When those dying of non-CV causes were combined with those known to be alive and compared with the CV group, the following respective differences emerged: age at initial study 
Discussion
The opportunity to obtain long-term (almost 30-year) follow-up data on a large diverse cohort of initially normotensive and hypertensive individuals has provided insight into factors associated with subsequent mortality. Not surprisingly, long-recognized factors such as age, gender, body mass index, and all measures of blood pressure (systolic, diastolic, mean arterial, and pulse pressures) were associated with a significant increase in the risk of death in our sample. This provides reassurance regarding the representativeness of our study cohort and its similarity with other populations. In addition, for the first time, salt sensitivity of blood pressure was found to be associated with mortality in normotensive as well as hypertensive subjects who were aged Ͼ25 years when they were initially studied. This finding is similar to previous observations in a smaller population of Japanese hypertensive subjects. 6 However, to our knowledge, this is the first demonstration of the increased risk of salt sensitivity in nonhypertensive individuals. Additional information is needed to understand the mechanisms by which salt sensitivity may contribute to mortality.
Among hypertensive subjects, salt sensitivity of blood pressure has been shown to increase with increasing age and to be more frequent in hypertensive than in normotensive subjects. 4 Age and blood pressure were associated with increased risk of mortality in our sample, as has been shown in many other studies. Thus, the link between salt sensitivity and increased risk of death among hypertensive subjects is Kaplan-Meier survival curves for normotensive salt-resistant subjects (NϩR), normotensive salt-sensitive subjects (NϩS), hypertensive salt-resistant subjects (HϩR), and hypertensive salt-sensitive subjects (NϩS) over the follow-up period. As noted, only the NϩR group had an increased survival.
not surprising. However, the observation of a decreased survival among initially normotensive individuals aged Ͼ25 years who were salt sensitive requires further consideration. We have previously reported that 26% of our normotensive population was salt sensitive. 4 We have also observed, during a 10-year follow-up of a small mixed group of subjects previously assessed for salt responsiveness of blood pressure, a significantly (PϽ0.001) greater rise in blood pressure with age and over time among those initially identified as salt sensitive compared with those who were salt resistant. 9 These observations suggest that salt-sensitive normotensive subjects may be at an increased risk for subsequent age-related hypertension. The ongoing analyses of the surviving subjects in our follow-up study may permit us to test the hypothesis that salt-sensitive normotensive subjects are more likely to develop hypertension with aging. This suggestion is supported by epidemiological findings indicating that age-related increases in blood pressure are observed only in societies in which the ambient sodium intake exceeds 50 to 100 mmol/ d. 10 If salt sensitivity of blood pressure is found to be associated with the future development of hypertension, it is possible that intervention in susceptible individuals, by reducing salt intake, could prevent or delay the subsequent age-related increase in blood pressure, the development of hypertension, and the increased risk of CV events and death.
